A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

by lowes1 on September 25, 2013

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Biological: 1121B (ramucirumab);   Drug: Pemetrexed;   Drug: Carboplatin (AUC 6);   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Carboplatin (AUC 5)
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting – verified September 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: